How to calculate the dose of chemotherapy

被引:182
作者
Gurney, H [1 ]
机构
[1] Westmead Hosp, Dept Med Oncol & Palliat Care, Westmead, NSW 2145, Australia
关键词
dose calculation; under-close; body surface area;
D O I
10.1038/sj.bjc.6600139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Body surface area-dosing does not account for the complex processes of cytotoxic drug elimination, This leads to an unpredictable variation in effect. Overdosing is easily recognised but it is possible that unrecognised underdosing is more common and may occur In 30% or more of patients receiving standard regimen. Those patients who are inadvertently underdosed are at risk of a significantly reduced anticancer effect. Using published data, it can be calculated that there is an almost 20% relative reduction in survival for women receiving adjuvant chemotherapy for breast cancer as a result of unrecognised underdosing. Similarly, the cure rate of cisplatir-based chemotherapy for advanced testicular cancer may be reduced by as much as 10%. The inaccuracy of body surface area-dosing is more than an inconvenience and it is important that methods for more accurate dose calculation are determined, based on the known drug elimination processes for cytotoxic chemotherapy. Twelve rules for dose calculation of chemotherapy are given that can be used as a guideline until better dose-calculation methods become available. Consideration should be given to using fixed dose guidelines independent of body surface area and based on drug elimination capability, both as a starting dose and for dose adjustment, which may have accuracy, safety and financial advantages. (C) 2002 Cancer Research UK.
引用
收藏
页码:1297 / 1302
页数:6
相关论文
共 40 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]   Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients [J].
Alexandre, J ;
Bleuzen, P ;
Bonneterre, J ;
Sutherland, W ;
Misset, JL ;
Guastalla, JP ;
Viens, P ;
Faivre, S ;
Chahine, A ;
Spielman, M ;
Bensmaïne, A ;
Marty, M ;
Mahjoubi, M ;
Cvitkovic, E .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :562-573
[3]  
[Anonymous], 1997, J Clin Oncol, V15, P594
[4]   Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer:: a randomised trial [J].
Bergh, J ;
Wiklund, T ;
Erikstein, B ;
Lidbrink, E ;
Lindman, H ;
Malmström, P ;
Kellokumpu-Lehtinen, P ;
Bengtsson, NO ;
Söderlund, G ;
Anker, G ;
Wist, E ;
Ottosson, S ;
Salminen, E ;
Ljungman, P ;
Holte, H ;
Nilsson, J ;
Blomqvist, C ;
Wilking, N .
LANCET, 2000, 356 (9239) :1384-1391
[5]   Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer [J].
Bishop, JF ;
Dewar, J ;
Toner, GC ;
Smith, J ;
Tattersall, MHN ;
Olver, IN ;
Ackland, S ;
Kennedy, I ;
Goldstein, D ;
Gurney, H ;
Walpole, E ;
Levi, J ;
Stephenson, J ;
Canetta, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2355-2364
[6]   Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer [J].
Budman, DR ;
Berry, DA ;
Cirrincione, CT ;
Henderson, IC ;
Wood, WC ;
Weiss, RB ;
Ferree, CR ;
Muss, HB ;
Green, MR ;
Norton, L ;
Frei, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (16) :1205-1211
[7]  
CARPENTER JT, 1982, CANCER, V50, P18, DOI 10.1002/1097-0142(19820701)50:1<18::AID-CNCR2820500105>3.0.CO
[8]  
2-J
[9]   Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American brain tumor consortium report [J].
Chang, SM ;
Kuhn, JG ;
Rizzo, J ;
Robins, HI ;
Schold, SC ;
Spence, AM ;
Berger, MS ;
Mehta, MP ;
Bozik, ME ;
Pollack, I ;
Gilbert, M ;
Fulton, D ;
Rankin, C ;
Malec, M ;
Prados, MD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2188-2194
[10]   AMPUTATION AND ADRIAMYCIN IN PRIMARY OSTEOSARCOMA [J].
CORTES, EP ;
HOLLAND, JF ;
WANG, JJ ;
SINKS, LF ;
BLOM, J ;
SENN, H ;
BANK, A ;
GLIDEWELL, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1974, 291 (19) :998-1000